The proto-oncogene product Bcl-2 protects a wide variety of cell types from apoptosis via a hitherto unknown mechanism. Bcl-2 has been shown to function upstream of the death proteases (caspases) in some, but not all, occurrences of apoptotic cell death. Using the myeloid leukemic cell line P39 we report the chemotherapy-induced caspase-dependent cleavage of endogenous Bcl-2. Etoposide treatment of these cells trig- 
Introduction
Apoptosis is an evolutionarily conserved and genetically controlled program for the efficient dismantling and elimination of damaged or potentially harmful cells. 1 The aspartate-specific proteases known as caspases are widely recognized as key players in the initiation and effector phases of apoptotic cell death. 2, 3 Diverse stimuli that cause apoptosis result in the activation of caspases, and caspase inhibitors, such as the cowpox virus protein CrmA and specific synthetic peptides, are potent inhibitors of apoptosis. 3 Caspases have been shown to specifically cleave and inactivate a number of proteins in apoptotic cells, including poly(ADP-ribose) polymerase (PARP), steroid response element binding proteins (SREBPs) and fodrin. 3 On the other hand, caspase-dependent cleavage may also result in the activation of cellular proteins such as mitogen-activated protein kinase kinase kinase (MEKK1), p21-activated kinase 2 (PAK2) and gelsolin, [4] [5] [6] and such proteolytically modified molecules may in turn amplify the apoptotic signal.
The proto-oncogene bcl-2 was first isolated from non-Hodgkin's follicular lymphoma cells harboring a t(14;18) chromosomal translocation. 7 Overexpression of Bcl-2 was later shown to prolong cell survival by inhibiting apoptosis, rather than by accelerating the rate of cell proliferation. 7 However, the precise mechanism of action of this proto-oncogene remains enigmatic. The Bcl-2 protein contains a stretch of hydrophobic amino acids that allows it to insert into intracellular membranes, primarily the outer mitochondrial membrane, nuclear envelope and endoplasmic reticulum, 8 and the principal role of Bcl-2 has recently been proposed to involve the prevention of cytochrome-c leakage from mitochondria. 9, 10 However, Bcl-2 has also been shown to affect cellular redox state, Ca 2+ homeostasis and protein transport, 11 demonstrating that the anti-apoptotic properties of Bcl-2 may not necessarily be restricted to its mitochondrial location. 12 Importantly, Bcl-2 and its congener Bcl-X L are known to regulate the activation of caspases. 11 This may occur either by preventing mitochondrial release of caspase-activating factors, such as cytochrome-c, 9, 10 or by sequestration and inhibition of caspases via interaction with the human CED-4 homologue, APAF-1 (apoptotic protease-activating factor-1; Refs 13 and 14) . Recent reports have demonstrated the caspase-dependent cleavage of Bcl-2 and Bcl-X L in tumor cells subjected to growth factor withdrawal, Sindbis virus infection or Fas/APO-1 ligation. 15, 16 Myelodysplastic syndromes (MDS) encompass a group of clonal stem cell disorders characterized by two distinct features: ineffective hematopoiesis and clonal evolution. 17 The former has lately been shown to be associated with an increased number of apoptotic bone marrow precursors 18 and is most likely the main cause of the severe pancytopenia observed in the early stages of the disease. 17 Clonal evolution and thus evasion from apoptotic surveillance may be related to the high incidence of leukemic transformation. 18 In the present study, we used a myeloid cell line originally derived from an individual suffering from overt leukemia following myelodysplastic syndrome 19, 20 to study the expression of Bcl-2 upon apoptosis induction. Our data demonstrate the occurrence of etoposide-induced Bcl-2 cleavage, and provide evidence that this is an early event in the apoptotic death of these cells. Interestingly, Bcl-2 cleavage was detected predominantly in the mitochondrial compartment, a finding which further underscores the central role of these organelles in apoptotic cell death. We propose that these myeloid leukemic cells possess different mechanisms for down-regulating the anti-apoptotic function of Bcl-2: either by decreased expression of Bcl-2 as shown to occur previously during differentiation of myeloid cells, 21, 22 or by proteolytic cleavage of Bcl-2 following apoptotic triggering. The latter mechanism may be an important factor in determining the susceptibility of tumor cells to chemotherapy.
Materials and methods

Reagents and cell culture
The agonistic anti-Fas mAb (clone CH-11) was purchased from Medical and Biological Laboratories (Nagoya, Japan). Etoposide (Vepesid, VP-16) was from Bristol-Myers (Solna, Sweden). DEVD-fmk (aspartate-glutamate-valine-aspartatefluoromethylketone), DEVD-CHO (aspartate-glutamate-valineaspartate-aldehyde), zVAD-fmk (benzyloxycarbonyl-valinealanine-aspartate-fluoromethylketone), IETD-fmk (isoleucineglutamate-threonine-aspartate-fluoromethylketone) and LEHD-fmk (leucine-glutamate-histidine-aspartate-fluoromethylketone) were purchased from Enzyme Systems Products (Dublin, CA, USA). DEVD-AMC (aspartate-glutamate-valineaspartate-7-amino-4-methyl-coumarin), YVAD-AMC, IETD-AMC and IETD-CHO were obtained from Peptide Institute (Osaka, Japan). Calpeptin and lactacystin were purchased from Biomol (Plymouth Meeting, PA, USA), and calpain inhibitor I was from Roche Diagnostics (Bromma, Sweden). The leukemic Jurkat T cell line was obtained from the European Collection of Cell Cultures (Salisbury, UK). The myelomonocytic leukemia cell line P39 was the generous gift of Professor Yataro Yoshida, Center for South East Asian Studies, Kyoto University, Kyoto, Japan. Cells were grown in RPMI-1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies, Paisley, UK). For apoptosis induction experiments, 1.5 × 10 6 cells/ml were incubated in the presence of etoposide (6 g/ml) or anti-Fas mAb (250 ng/ml) for the times indicated.
Morphological assessment
Cytospin preparations of P39 cells were stained with MayGrü nwald-Giemsa solution and photographed under the light microscope at 1250× magnification. Apoptotic cells were identified by virtue of their chromatin condensation and the formation of apoptotic bodies. A minimum of 400 cells were counted per sample.
Agarose gel electrophoresis
DNA fragmentation was assessed by one-stage agarose gel electrophoresis as described previously. 23 Briefly, 1.5 × 10 6 cells were washed and resuspended in sample buffer containing RNase (10 mg/ml) for 20 min. Samples were then loaded on to a 1.8% agarose gel with a digestion gel (0.8% Ultrapure agarose, 2% SDS and 0.6 mg/ml proteinase K) at the upper end. The gel was run at 20 V overnight and electrophoresis was then continued for 3 h at 90 V to separate the DNA fragments. The gel was subsequently incubated with RNase (50 mg/ml) for 4 h, stained with ethidium bromide, and photographed under 305 nm UV illumination using Polaroid 665 positive/negative film (Polaroid, Cambridge, MA, USA).
Western blot analysis
Samples were lysed in Laemmli buffer and boiled for 5 min. Proteins were then separated at 130 V on 12% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose filters for 2 h at 100 V. Membranes were blocked over- 
In vitro caspase assay
The measurement of DEVD-AMC, IETD-AMC and YVAD-AMC cleavage was performed in a fluorometric assay modified from Nicholson et al. 24 Cell lysates and the appropriate peptide substrate (DEVD-AMC, IETD-AMC or YVAD-AMC) were combined in a standard reaction buffer (100 mM HEPES, 10% sucrose, 5 mM dithiothreitol (DTT) and 0.1 % 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate (CHAPS), pH 7.25) and added to a microtiter plate. Cleavage of the fluorogenic peptide substrate was monitored by AMC liberation in a Fluoroscan II plate reader (Labsystems, Stockholm, Sweden) using 355 nm excitation and 460 nm emission wavelengths. Fluorescence units were converted to pmol of AMC using a standard curve generated with free AMC. Data from duplicate samples were then analyzed by linear regression.
Subcellular fractionation of P39 cells
Untreated or etoposide-treated P39 cells (400 × 10 6 ) were washed once with buffer A (100 mM sucrose, 1 mM EGTA, 20 mM MOPS [4-morpholinepropanesulfonic acid], pH 7.4), then resuspended in buffer B (buffer A plus 5% Percoll, 0.01% digitonin, and a cocktail of protease inhibitors containing: 10 M aprotinin, 10 M pepstatin A, 10 M leupeptin and 1 mM PMSF (␣-phenylmethylsulfonyl fluoride)). After incubation on ice for 15 min, the suspension was centrifuged to remove intact cells and nuclei (2500 g, 10 min). The mitochondria were then pelleted by centrifugation at 15 000 g for 15 min and resuspended in buffer C (300 mM sucrose, 1 mM EGTA, 20 mM MOPS, pH 7.4, supplemented with the protease inhibitors). The supernatant was further centrifuged at 100 000 g for 1 h. The resultant supernatant was designated as cytosol and the pellet as the microsomal fraction (ie endoplasmic reticulum/low density vesicles). The nuclear pellet was resuspended in 10 mM Tris-HCl, pH 7.5, 2.5 mM KCl, 2.5 mM MgCl 2 and isolated after centrifugation at 90 000 g for 30 min through 2.1 M sucrose, containing 50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 . All steps were performed on ice or at 4°C. Finally, equal amounts of protein (12 g) were electrophoresed on 12% SDS-polyacrylamide gels and immunoblotted as described above. In some experiments, samples were adjusted for equal amounts of Bcl-2 prior to loading, and immunoblots were subsequently subjected to densitometric analysis using a BioRad Gel Doc 1000 densitometer and Molecular Analyst software (BioRad Laboratories, Hercules, CA, USA). The percent cleavage of Bcl-2 was calculated as the amount of 23 kDa product formed relative to the total amount of 26 kDa and 23 kDa protein after etoposide treatment. Purity of the mitochondrial, cytosolic, microsomal and nuclear fractions was assessed using specific enzyme markers, ie NADH-and NADPH-cytochrome-c reductase and lactate dehydrogenase (LDH), as well as Western blotting using compartment-specific antibodies directed against cytochrome-c and lamin B, as described previously. 25 
Results
Activation of type II and type III caspases during etoposide-induced apoptosis of P39 cells
The topoisomerase poison etoposide has been shown to induce apoptosis in a variety of cell types. [26] [27] [28] Similarly, we could demonstrate a time-dependent apoptotic response in the myelomonocytic cell line P39 treated with etoposide (6 g/ml) as evidenced by morphological changes and internucleosomal fragmentation of DNA (Figure 1a Based on the preferred tetrapeptide recognition motif, the caspases have been assigned to three subgroups designated type I, type II and type III caspases. 29 Moreover, caspase activation can be determined in vitro using fluorogenic substrates which mimic the specific recognition sites of the different caspases. 24 Hence, we incubated extracts from cells treated with etoposide for up to 12 h with the fluorogenic substrates IETD-AMC, DEVD-AMC or YVAD-AMC. The first two substrates are specifically recognized and cleaved by type III or 'activator' caspases (ie caspase-6, -8 and -9) and type II or 'effector' caspases (including caspase-3 and -7), respectively, whereas cleavage of the latter substrate is indicative of type I or caspase-1-like activity. 29 In agreement with previous studies performed in the myeloid cell line HL-60 (Ref. 30 ), we could detect no caspase-1-like activity in P39 cells following etoposide treatment (Figure 2a) . DEVD-AMC cleavage, however, was markedly increased over time, with a 10-fold increase in activity within 12 h of the addition of etoposide, and a modest increase in IETD-AMC cleavage was also evident (Figure 2a ). For comparison, the time-course of DEVD-AMC cleavage activity in the Jurkat cell line was similar when compared to P39 cells (data not shown). To confirm the specificity of the cellular extracts for the DEVD-AMC and IETD-AMC peptide substrates, the competitive aldehyde inhibitor DEVD-CHO or IETD-CHO was added to the cell lysates, and found to inhibit substrate cleavage (Figure 2b and c) . To further demonstrate the activation of caspase-3 in etoposidetreated P39 cells, cell lysates were subjected to immunoblot analysis using a caspase-3 specific antibody. As seen in Figure 2d , treatment of these cells with etoposide results in a time-dependent processing of the 32 kDa caspase-3 zymogen into the 17 kDa active protease.
Cleavage of Bcl-2 in P39 cells undergoing etoposideinduced apoptosis
In order to evaluate the expression and/or integrity of Bcl-2 in P39 cells following apoptotic triggering, cells were treated with etoposide (6 g/ml) for 24 h and the level of Bcl-2 was determined by Western blot at different time points. Bcl-2 was found to be cleaved in a time-dependent manner yielding a cleavage fragment of approximately 23 kDa (Figure 3a) . Subsequent analysis of additional tumor cell lines of myeloid origin, including monocytic U937 cells and promyelocytic HL-60 cells, demonstrated that etoposide-triggered Bcl-2 cleavage occurs also in these cell lines (data not shown). For comparison, levels of the pro-apoptotic protein Bax remained unaffected following etoposide treatment, as determined by immunoblot analysis using anti-Bax antibodies directed against amino acids 3-16 and 43-61, respectively (data not shown). Caspases cleave their substrates at the carboxyl side of aspartate residues, and examination of the Bcl-2 sequence reveals several putative caspase cleavage sites. 7 In an attempt to define the cleavage site within Bcl-2, cell lysates from control and etoposide-treated samples were probed with antibodies raised against the N-terminal portion (amino acids 4-21) and the variable loop domain (amino acids 41-54), respectively. As seen in Figure 4a , both antibodies recognized the full-length Bcl-2 protein, whereas only the latter antibody could detect the 23 kDa cleavage product. These results indicate that the cleavage fragment is devoid of the N-terminal epitope targeted by the Bcl-2 antibody 4-21, while the epitope recognized by the antibody 41-54 is retained. The data are therefore compatible with cleavage at Asp residues 31 and/or 34 contained within the variable loop region (Figure 4b ).
Effect of various protease inhibitors on etoposideinduced Bcl-2 cleavage
Although direct evidence for caspase cleavage of Bcl-2 is lacking in the present study, the fragment we detected is identical in size to that reported by Cheng et al 15 following incubation of in vitro translated Bcl-2 with purified recombinant caspase-3. To obtain further support for the notion that Bcl-2 cleavage was caspase-dependent, we incubated etoposide-treated P39 cells in the presence or absence of the general caspase inhibitor zVAD-fmk for 12 h. As seen in Figure 3b , cleavage of Bcl-2 was completely abrogated under these conditions. To further probe the role of individual proteases in this event, a panel of peptide-based inhibitors was screened for their ability to block etoposide-induced cleavage of Bcl-2. As seen in Figure 3c , preincubation of the cells with the type III caspase inhibitor IETD-fmk, as well as the caspase-9-like inhibitor LEHD-fmk blocked Bcl-2 cleavage as efficiently as zVAD-fmk, whereas the type II caspase or caspase-3-like inhibitor DEVD-fmk afforded only partial protection. However, DEVD-fmk effectively blocked PARP cleavage in these cells (data not shown). Interestingly, in the presence of the calpain inhibitors (calpain inhibitor I and calpeptin) and the proteasome inhibitor lactacystin, Bcl-2 cleavage was, in fact, enhanced (Figure 3c ). Thus, these inhibitor studies indicate that Bcl-2 cleavage is, indeed, caspase-mediated and implicate type III caspases, rather than type II caspases, in this event. 
Bcl-2 cleavage precedes cleavage of the known caspase substrates PARP and lamin B
Caspase-3 and caspase-6 were previously shown to be the most abundant caspase species present in etoposide-treated tumor cells of different origin. 30, 31 Moreover, Kaufmann et al 26, 32 have shown that the known caspase-3 substrate poly(ADP-ribose) polymerase (PARP) as well as lamin B (a caspase-6 substrate) are proteolytically cleaved in HL-60 cells in response to etoposide treatment. To further delineate the timecourse of etoposide-induced Bcl-2 cleavage in the P39 cell line, the cleavage of PARP and lamin B was evaluated in these cells and compared to the proteolysis of Bcl-2. The characteristic 85 kDa PARP fragment appeared approximately at 6 h following etoposide treatment (Fig. 5) . Similarly, cleavage of lamin B was evident after 6 h ( Figure 5 ). However, when these membranes were reprobed with Bcl-2-specific antibodies, we could detect the emergence of the 23 kDa fragment already at 2 h ( Figure 5 ), indicating that Bcl-2 cleavage preceded both PARP and lamin B cleavage.
Cleavage of Bcl-2 detected predominantly in the mitochondrial compartment of P39 cells
Bcl-2 is an integral membrane protein that localizes predominantly to the mitochondria, but is also present in the smooth endoplasmic reticulum and the perinuclear envelope. 8 In an attempt to determine whether Bcl-2 cleavage occurred preferentially in either of these compartments, untreated and etoposide-treated P39 cells were subjected to subcellular fractionation as described in Materials and methods. To confirm the purity of the various fractions, each fraction was first tested for cross-contamination with cytosol and microsomes. More than 93% of lactate dehydrogenase (LDH) activity (a cytoplasmic marker) was found in cytosol, whereas very low levels of this enzyme activity were detected in mitochondria (2.3 ± 0.4%), nuclei (1.2 ± 0.08%) and microsomes (2.6 ± 0.5%), respectively. Activity of NADH-and NADPHcytochrome-c reductase (marker enzymes for microsomes) was found mainly in the microsomal fraction (more than 90% for both enzymes). No more than 2.4 ± 0.7% of NADH-cytochrome-c reductase activity was detected in cytosol, 4.5 ± 0.6% in mitochondria and 2.5 ± 0.2% in nuclear fractions, respectively. The activity of NADPH-cytochrome-c reductase was 2.9 ± 0.3% in cytosol, 6.8 ± 0.5% in mitochondria and 1.9 ± 0.1% in nuclei, respectively. In addition, Western blotting was carried out to determine the levels of crosscontamination of the cytoplasmic and microsomal fractions with mitochondria and nuclear fragments, using anti-cytochrome-c and anti-lamin B antibodies. Figure 6a shows that cytochrome-c and lamin B detection was limited to mitochondrial and nuclear fractions, respectively, and that other fractions were uncontaminated with these subcellular compartments as judged by this criterion. In agreement with earlier studies of hematopoietic cells, 11 Bcl-2 was found to reside primarily in the mitochondrial and nuclear fractions of P39 cells with small amounts present also in the microsomal fraction (Figure 6a ). The doublet band in the cytosolic fraction of P39 cells is smaller than 26 kDa in size and is the result of unspecific binding of these antibodies with unknown proteins. Bcl-2 cleavage was detected only in the mitochondrial fraction of these cells, with no cleavage product present in the microsomal or nuclear fraction, despite equal loading of protein in each lane (Figure 6a ). To further clarify whether cleavage of Bcl-2 is confined to the mitochondrial compartment, etoposide-treated samples were adjusted for equal amounts of Bcl-2, rather than total protein, prior to loading. As seen in Figure 6b , cleavage of Bcl-2 was evident under these conditions also in the microsomal and nuclear fractions. However, subsequent densitometric analysis demonstrated that the percentage of Bcl-2 cleavage was two-to three-fold greater in the mitochondrial fraction (Figure 6b ). The fact that both intact and proteolytically cleaved Bcl-2 are present in all fractions except in the cytosol indicates that cleavage does not affect the membrane anchorage of Bcl-2, and these findings therefore concur with our epitope mapping of the Bcl-2 cleavage site described in a previous section. Based on our quantitative analysis, these data demonstrate that Bcl-2 is predominantly cleaved in the mitochondrial compartment following etoposide treatment. Bcl-2 proteolysis precedes cleavage of poly(ADP-ribose) polymerase (PARP) and lamin B. The cleavage of the caspase substrates PARP (upper panel) and lamin B (middle panel) was examined in apoptotic P39 cells. P39 cells were treated with etoposide (6 g/ml) for the indicated time points and subjected to Western blotting as described above. The characteristic 85 kDa PARP fragment and the 46 kDa lamin B cleavage product are arrowed. The same membranes were then reprobed with Bcl-2-specific antibodies (lower panel). The blots are representative of three similar experiments.
Discussion
The present study demonstrates that the anti-apoptotic molecule Bcl-2 is a substrate for cleavage in myeloid leukemic cells treated with the chemotherapeutic agent etoposide. Cleavage of Bcl-2 was associated with caspase activation and the emergence of the 23 kDa cleavage fragment was zVADfmk-inhibitable, indicating that this was a caspase-dependent event. Importantly, cleavage of Bcl-2 was seen already after 2 h following etoposide treatment and preceded cleavage of
Figure 6
Bcl-2 cleavage occurs predominantly in the mitochondrial compartment. (a) Following 18 h of incubation in the presence or absence of etoposide (6 g/ml), P39 cells were subjected to subcellular fractionation as described in Materials and methods. Equal amounts of total protein (12 g) derived from the (1) mitochondrial, (2) cytosolic, (3) microsomal and (4) nuclear fractions were then loaded on SDS-PAGE gels and membranes were probed with Bcl-2 specific antibodies. To control for the purity of these fractions, membranes were reprobed with various compartment specific antibodies as shown (see text for details). Similar results were obtained in two independent experiments. (b) Subcellular fractions 1-4 from etoposide-treated cells were adjusted for the amount of Bcl-2 protein, and samples were loaded on SDS-PAGE gels and probed as above with Bcl-2 specific antibodies. Immunoblots were subsequently subjected to densitometric analysis as described in Materials and methods and the percent cleavage of Bcl-2 was calculated.
PARP and lamin B, two known caspase substrates of nuclear localization. These results are not due to a lack of sensitivity of the antibodies used for Western blot analysis, since PARP cleavage in a different model, ie. Fas-triggered Jurkat cells, can be detected already within 15 min (unpublished observations). Therefore, we consider Bcl-2 cleavage an early step in the apoptotic cascade in myeloid cells, rather than a secondary event resulting from wholesale proteolytic destruction of cellular proteins.
Since the inception of these studies, three groups have documented caspase-mediated cleavage of Bcl-2 and/or Bcl-X L in several different mammalian cell types following either Fas/APO-1 triggering, growth factor withdrawal or alphavirus infection. 15, 16, 33, 34 Our findings thus extend this novel phenomenon to include also chemotherapy-induced death of tumor cells. However, the question of which caspase is responsible for Bcl-2 cleavage following different apoptotic stimuli has not been conclusively resolved. Cheng et al 15 provided direct evidence for caspase-3-mediated cleavage of Bcl-2 in vitro, whereas Grandgirard et al 33 appeared to exclude caspases 3 and/or 7, at least in the case of alphavirus-induced Bcl-2 cleavage. Clem et al 16 showed that both caspase-1 and caspase-3 could cleave the related Bcl-2 family member Bcl-X L , although the importance of caspase-1 activation for apoptosis remains unclear. 2 On the other hand, Fujita et al 34 have demonstrated that Bcl-X L cleavage is blocked by inhibitors of caspase-3-like, but not caspase-1-like, enzymes. Finally, Yamamoto et al 35 recently reported the cleavage of Bcl-2 by a non-caspase protease in the B cell lymphoma cell line RL-7 treated with the Zn chelator TPEN. In the present study, we could detect the activation of type II and type III caspases in etoposide-treated cells, as evidenced by the in vitro cleavage of the corresponding fluorogenic substrates, and subsequent cleavage of Bcl-2. Our epitope mapping indicates that cleavage of Bcl-2 occurs within the variable loop region, which contains two canonical caspase cleavage sites, and thus serves to remove the N-terminus of Bcl-2 with its BH4 domain which is essential to promote cell survival (Figure 4b ). In addition, our inhibitor studies indicate a role for IETD-fmk-and LEHD-fmk-inhibitable proteases such as caspase-6, -8 and -9, in the cleavage of Bcl-2, although we cannot, based solely on these inhibitor data, exclude a role for DEVD-specific enzymes (ie caspase-3 and -7) in this event. Interestingly, the calpain and proteasome inhibitors failed to block Bcl-2 cleavage, rather, cleavage of Bcl-2 appeared to be enhanced under these conditions. Cells incubated in the presence of these inhibitors also consistently displayed higher levels of DEVD-AMC cleavage in vitro (unpublished observations), suggesting that inhibition of calpain and/or proteasome function may ameliorate caspase activity. The significance of these findings is presently not well understood. Nevertheless, the fact that we could detect the presence of the Bcl-2 fragment well before cleavage of PARP and lamin B occurred, supports the contention that perhaps different caspases may be responsible for cleavage of these substrates. To add further to the complexity of this event, caspase-3 has been found to have a mitochondrial as well as a cytosolic localization, 25, 36 and we have recently procured evidence for the mitochondrial localization of additional caspases, including caspase-9 (Zhivotovsky et al, submitted for publication). Our current data therefore raise the intriguing question of whether mitochondrial caspases are activatable and, if so, whether Bcl-2 may serve as a substrate for such a mitochondrial caspase. The fact that we could detect Bcl-2 cleavage predominantly in the mitochondrial fraction of etoposidetreated P39 cells further underlines the pivotal role of mitochondrial events in apoptosis (the cleavage of Bcl-2 which we observed in the microsomal and nuclear fraction was seen only under 'unphysiological' conditions, ie when extreme amounts of protein from these fractions, relative to the mitochondrial fraction, were loaded on the gel). Since the regulation of cytochrome-c release from mitochondria has been suggested to be a primary role for Bcl-2, 9,10 it is feasible that caspase-mediated cleavage of Bcl-2 may lead to an increased leakage of cytochrome-c from the mitochondria with an ensuing activation of additional cytosolic caspases, thus serving as a feed-forward amplification loop for apoptosis signaling. Further work is clearly required to dissect the role of mitochondrial Bcl-2 cleavage.
The prevailing paradigm with regards to Bcl-2 function has held that the relative ratios of Bcl-2 and Bax heterodimers to homodimers will determine the propensity of a cell to die by apoptosis. 7 Alternatively, as proposed by Otter et al 37 recently, the amount of Bcl-2 free of Bax, rather than the Bcl-2/Bax heterodimer ratio, may determine the degree of protection against apoptosis. Interestingly, the myeloid cell line P39 which we employed in the present study exhibits elevated levels of Bcl-2 compared to the leukemic T cell line Jurkat and the myeloid cell lines HL-60 and U937, while Bax levels in P39 cells were similar compared to those found in the other myeloid cell lines (unpublished observations). Therefore, in P39 cells, where the level of free Bcl-2 may be construed to be relatively high, cleavage and subsequent inactivation of Bcl-2 could represent a prerequisite for the apoptotic signal to be efficiently propagated. Indeed, Clem et al 16 have presented evidence that the ratio of cleaved vs full length Bcl-X L is important in determining susceptibility to cell death. Although the potential ramifications of Bcl-2 cleavage were not specifically addressed in our study, these are likely to include loss of the anti-apoptotic function of Bcl-2 (see above). The fact that Bcl-2 cleavage occurred at an early stage following etoposide treatment lends support to the notion that caspase cleavage serves to incapacitate this abundant apoptosis inhibitor. However, a novel role for the 23 kDa fragment cannot be excluded. In fact, Cheng et al 15 suggested that the caspase-3-induced cleavage product of Bcl-2 may possess pro-apoptotic activity, thus adding further to the apoptotic insult of the dying cell. Interestingly, Xue and Horvitz showed recently that Ced-9, the Bcl-2 homologue in the nematode Caenhorabditis elegans, is a substrate for the caspase-like protease Ced-3, 38 although in this case the anti-apoptotic function of Ced-9 was retained. Nevertheless, these findings indicate that proteolytic modification of Bcl-2-like molecules may be an evolutionarily conserved feature of the apoptotic program.
Resistance to chemotherapy is a major concern in cancer treatment. 39 Several investigators have suggested that deregulated apoptosis may contribute to chemotherapy resistance. 40 One way to overcome such resistance is to downregulate Bcl-2 function.
11 Notably, the tumor suppressor p53 has been shown to function as a repressor of bcl-2 gene expression, 41 and differentiation of myeloid cells is known to cause downregulation of Bcl-2. 21, 22 Post-translational events such as hyperphosphorylation of Bcl-2 may also play an important role in this respect. 42, 43 The chemotherapy-induced cleavage of Bcl-2 in tumor cells documented in the present study represents another possible mechanism for the inactivation of Bcl-2, and this event may serve to determine the susceptibility of tumor cell to apoptosis. The question whether Bcl-2 cleavage occurs also in cells from MDS patients is currently under investigation in our laboratory. To conclude, myeloid leukemic cell lines such as P39 appear to possess distinct mechanisms for the attenuation of the anti-apoptotic function of Bcl-2, ie differentiation-induced downregulation and chemotherapy-mediated cleavage of Bcl-2. Future studies will address the question of whether this is a general feature of chemotherapy-induced caspase activation in tumor cells.
